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Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that 
lead to poor anti-tumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has 
been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was 
shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 
through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 
that penetrated through the MCL was quantitated by utilizing high performance liquid 
chromatography (HPLC). Histopathological staining was used to visualize the morphology of 
MCL. A chemosensitivity assay was performed to assess the anti-cancer activity of SRJ09 in 
DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional 
with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90 ± 0.20 
μM/min/cm2 and 0.56 ± 0.06 μM/min/cm2 for days 1 and 5, respectively, which are better 
than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 
MCL was retained and no visible damage was inflicted on the cell membrane, confirming the 
penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells 
demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than 
andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully 
penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be 
developed as a clinically viable anti-colon cancer drug. 
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